New insider activity at Nautilus Biotechnolgy ( (NAUT) ) has taken place on September 5, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
GC Matthew B. Murphy has made a significant investment in Nautilus Biotechnology by purchasing 20,000 shares of the company’s stock, valued at $12,800.
Spark’s Take on NAUT Stock
According to Spark, TipRanks’ AI Analyst, NAUT is a Neutral.
Nautilus Biotechnology’s score reflects its early-stage status with high operational losses and zero revenue, typical for biotech firms focused on R&D. While its strong cash reserves and low leverage offer some stability, persistent losses and slow pharma partnerships pose significant risks. Technical indicators suggest a bearish trend, but the earnings call highlighted positive advancements in proteomics and cost efficiencies, offering a cautiously optimistic outlook.
To see Spark’s full report on NAUT stock, click here.
More about Nautilus Biotechnolgy
YTD Price Performance: -61.48%
Average Trading Volume: 319,213
Technical Sentiment Signal: Sell
Current Market Cap: $82.33M